Tagrisso Found Superior to Alimta-Chemo Combo in Specific NSCLC Patients, Trial Shows
News
Results from the Phase 3 AURA study show that Tagrisso (osimertinib) is clinically superior to the combination of Alimta (pemetrexed) plus platinum-based chemotherapy in the treatment of certain patients with non-small-cell ... Read more